Bank of New York Mellon’s Amphastar Pharmaceuticals AMPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.69M Sell
232,343
-10,883
-4% -$220K ﹤0.01% 2475
2026
Q1
$4.76M Sell
243,226
-15,835
-6% -$387K ﹤0.01% 2340
2025
Q4
$6.94M Sell
259,061
-8,767
-3% -$226K ﹤0.01% 2130
2025
Q3
$7.14M Sell
267,828
-46,975
-15% -$1.21M ﹤0.01% 2121
2025
Q2
$7.23M Buy
314,803
+48,728
+18% +$1.21M ﹤0.01% 2063
2025
Q1
$7.71M Sell
266,075
-19,788
-7% -$632K ﹤0.01% 1995
2024
Q4
$10.6M Buy
285,863
+32,112
+13% +$1.47M ﹤0.01% 1895
2024
Q3
$12.3M Sell
253,751
-36,203
-12% -$1.59M ﹤0.01% 1821
2024
Q2
$11.6M Sell
289,954
-4,529
-2% -$188K ﹤0.01% 1882
2024
Q1
$12.9M Sell
294,483
-18,855
-6% -$974K ﹤0.01% 1830
2023
Q4
$19.4M Sell
313,338
-13,169
-4% -$692K ﹤0.01% 1613
2023
Q3
$15M Sell
326,507
-15,614
-5% -$852K ﹤0.01% 1700
2023
Q2
$19.7M Sell
342,121
-5,091
-1% -$226K ﹤0.01% 1564
2023
Q1
$13M Buy
347,212
+1,196
+0.3% +$39.2K ﹤0.01% 1788
2022
Q4
$9.7M Sell
346,016
-16,859
-5% -$490K ﹤0.01% 1958
2022
Q3
$10.2M Sell
362,875
-2,971
-0.8% -$97K ﹤0.01% 1890
2022
Q2
$12.7M Sell
365,846
-35,559
-9% -$1.27M ﹤0.01% 1798
2022
Q1
$14.4M Buy
401,405
+30,462
+8% +$864K ﹤0.01% 1870
2021
Q4
$8.64M Buy
370,943
+6,943
+2% +$142K ﹤0.01% 2180
2021
Q3
$6.92M Buy
364,000
+8,452
+2% +$166K ﹤0.01% 2330
2021
Q2
$7.17M Sell
355,548
-23,135
-6% -$436K ﹤0.01% 2312
2021
Q1
$6.94M Sell
378,683
-7,669
-2% -$143K ﹤0.01% 2285
2020
Q4
$7.77M Buy
386,352
+327
+0.1% +$6.36K ﹤0.01% 2135
2020
Q3
$7.24M Buy
386,025
+8,421
+2% +$170K ﹤0.01% 2031
2020
Q2
$8.48M Buy
377,604
+4,624
+1% +$84.7K ﹤0.01% 1932
2020
Q1
$5.54M Sell
372,980
-15,785
-4% -$275K ﹤0.01% 2029
2019
Q4
$7.5M Buy
388,765
+5,444
+1% +$104K ﹤0.01% 2137
2019
Q3
$7.6M Sell
383,321
-6,577
-2% -$137K ﹤0.01% 2078
2019
Q2
$8.23M Sell
389,898
-10,482
-3% -$219K ﹤0.01% 2073
2019
Q1
$8.18M Sell
400,380
-46,748
-10% -$1.05M ﹤0.01% 2079
2018
Q4
$8.9M Buy
447,128
+28,225
+7% +$556K ﹤0.01% 1972
2018
Q3
$8.06M Buy
418,903
+10,837
+3% +$193K ﹤0.01% 2151
2018
Q2
$6.23M Sell
408,066
-6,322
-2% -$110K ﹤0.01% 2277
2018
Q1
$7.77M Buy
414,388
+9,599
+2% +$180K ﹤0.01% 2117
2017
Q4
$7.79M Sell
404,789
-51,367
-11% -$959K ﹤0.01% 2112
2017
Q3
$8.15M Sell
456,156
-22,490
-5% -$370K ﹤0.01% 2087
2017
Q2
$8.55M Sell
478,646
-41,156
-8% -$653K ﹤0.01% 2064
2017
Q1
$7.54M Buy
519,802
+53,214
+11% +$837K ﹤0.01% 2110
2016
Q4
$8.6M Buy
466,588
+31,864
+7% +$620K ﹤0.01% 2032
2016
Q3
$8.25M Buy
434,724
+243,875
+128% +$4.43M ﹤0.01% 1970
2016
Q2
$3.08M Buy
190,849
+62,731
+49% +$885K ﹤0.01% 2478
2016
Q1
$1.54M Buy
128,118
+3,176
+3% +$37.4K ﹤0.01% 2818
2015
Q4
$1.78M Hold
124,942
﹤0.01% 2788
2015
Q3
$1.46M Buy
124,942
+2,429
+2% +$36.4K ﹤0.01% 2933
2015
Q2
$2.15M Buy
122,513
+87,722
+252% +$1.37M ﹤0.01% 2866
2015
Q1
$521K Buy
34,791
+7,574
+28% +$101K ﹤0.01% 3587
2014
Q4
$316K Buy
27,217
+6,175
+29% +$67.3K ﹤0.01% 3766
2014
Q3
$246K Buy
+21,042
New +$219K ﹤0.01% 3837

Other funds holding AMPH

Bank of New York Mellon's AMPH Position: Q2 2026 in Review

Bank of New York Mellon reduced its Amphastar Pharmaceuticals (AMPH) stake by 4.5% in Q2 2026, selling an estimated $220K and leaving 232,343 shares worth $4.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2475.

Bank of New York Mellon first reported a position in AMPH in Q3 2014 and has held it in 48 quarters since. The position peaked at $19.7M in Q2 2023. 70 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Bank of New York Mellon held 232,343 shares of Amphastar Pharmaceuticals worth $4.69M as of Q2 2026.
  • Bank of New York Mellon sold 10,883 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $220K.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2475 holding.
  • Bank of New York Mellon first reported a position in Amphastar Pharmaceuticals in Q3 2014 and has held it in 48 quarters since.
  • Bank of New York Mellon's Amphastar Pharmaceuticals position peaked at $19.7M in Q2 2023.
  • 70 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.